Device Trial Radar · NCT01934218
Gel-One Treatment in Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Seikagaku CorporationNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Zimmer Biomet
- First posted
- Sep 4, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Gel-One demonstrates a superior effectiveness in osteoarthritis (OA) knee pain compared with phosphate buffered saline (PBS) injections.
Conditions
- Osteoarthritis Knee
Interventions
Gel-OneDevice
PBSDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Visual Analogue Scores (VAS) Following 50-foot Walk Test Through Week 26Time frame: Baseline up to Week26
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
40 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.